**Experimental approaches in personalised medicine in urothelium tumours**

**Poster Session 39**

**Location:** Room Madrid, North Hall (Level 1)

**Chairs:**
- F. Deho, Milan (IT)
- M. Knowles, Leeds (GB)
- M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)

**Aims and objectives of this session**
The course of bladder cancer could be affected by many factors. In order to predict the course of the disease, it is important to analyze multiple parameters. Studies presented in this session will focus also on exosomes and miRNA.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

519

**Tumor-associated exosomes of urothelial bladder cancer cells affect tumor-promoting processes in normal bladder fibroblasts and support tumorigenesis**

By: 
- Baumgart S.¹
- Heinzelmann J.¹
- Krause E.²
- Stöckle M.¹
- Stampe Ostenfeld M.³
- Junker K.¹

**Institutes:**
- Saarland University Medical Center, Dept. of Urology, Homburg, Germany
- Saarland University Medical Center, Dept. of Physiology, Homburg, Germany
- University Hospital Aarhus, Dept. of Molecular Medicine, Aarhus, Denmark

520

**Cancer-associated fibroblasts secreted exosomal miR-146a promotes bladder cancer progression**

By: 
- Zhuang J.¹
- Shen L.²
- Yan J.²
- Guo H.¹

**Institutes:**
- Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China
- MOE Key Laboratory of Model Animals For Disease Study, Model Animal Research Center, Dept. of Tumor Biology, Nanjing, China

521

**Genomic landscape of upper urinary tract urothelial carcinoma**

By: 
- Fujii Y.¹
- Sato Y.¹
- Suzuki H.²
- Shiozawa Y.²
- Yoshizato T.²
- Yoshida K.²
- Shiraishi Y.²
- Nakagawa T.¹
- Kume H.¹
- Nishimatsu H.²
- Okane T.³
- Sanada M.⁴
- Makishima H.²
- Ogawa S.²
- Homma Y.¹

**Institutes:**
- The University Of Tokyo Hospital, Dept. of Urology, Bunkyo, Japan
- Graduate School of Medicine Kyoto University, Dept. of Pathology and Tumor Biology, Kyoto, Japan
- Institute of Medical Science The University of Tokyo, Laboratory of DNA Information Analysis, Human Genome Center, Minato, Japan
- The Fraternity Memorial Hospital, Dept. of Urology, Sumida, Japan
- Toranomon Hospital, Dept. of Urology, Minato, Japan
- Nagoya Medical Center, Advanced Diagnosis, Clinical Reserach Center, Nagoya, Japan

522

**Molecular subtype classification of advanced bladder cancer and matched lymph-node metastases by integrative immunohistochemistry, gene expression, and mutation analyses**

By: 
- Sjödahl G.¹
- Eriksson P.²
- Lövgren K.²
- Liedberg F.¹
- Höglund M.²

**Institutes:**
- Translational Medicine, Dept. of Urologic Research, Lund, Sweden
- Clinical Sciences, Dept. of Oncology and Pathology, Lund, Sweden

523

**Withdrawn**

By:

**Institutes:**

524

**Urine based DNA methylation biomarkers for monitoring bladder cancer**

By: 
- Van Der Heijden A.²
- Mengual L.¹
- Ingelmo-Torres M.¹
- Lozano J.³
- Van Rijt-Van De Westerlo C.⁴
525

Utilization of next-generation sequencing techniques to investigate markers for chemosensitivity in bladder cancer patients treated with neoadjuvant chemotherapy prior to radical cystectomy
By: Bostöm P.1, Fey V.2, Kaakinen E.3, Lamminen T.1, Laitinen A.1, Mirtti T.4, Koskinen I.5, Salminen A.1, Taimen P.6, Schleutker J.3
Institutes: 1Turku University Hospital, Dept. of Urology, Turku, Finland, 2University of Turku, Institution of Biotechnology, Turku, Finland, 3Turku University, Dept. of Medical Biochemistry and Genetics, Turku, Finland, 4Helsinki University Hospital and Finnish Institute For Molecular Medicine, University of Helsinki, Dept. of Pathology (HUslab), Helsinki, Finland, 5Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 6Turku University Hospital, Dept. of Pathology, Turku, Finland

526

Bladder cancer-secreted extracellular vesicles destroy vascular endothelial barriers
By: Yoneyama M.S.1, Hatakeyama S.2, Funyu T.3, Tsuboi S.1, Ohyama C.2
Institutes: 1Oyokyo Kidney Research Institute, Dept. of Cancer Immunology and Cell Biology, Hirosaki, Japan, 2Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 3Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan

527

KRT5 and KRT20 expression predicts recurrence and progression of stage pT1 non-muscle-invasive bladder cancer (NMIBC)
By: Breyer J.1, Wirtz R.2, Denzinger S.1, Erben P.3, Kriegsmann M.3, Stoehr R.4, Eckstein M.4, Burger M.1, Otto W.1, Hartmann A.4
Institutes: 1University of Regensburg, Dept. of Urology, Regensburg, Germany, 2Stratifyer Molecular Pathology GmbH, Cologne, Germany, 3University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, 4University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany

528

Cell-free DNA from urine samples – a valuable source for bladder cancer biomarkers?
By: Salomo K., Moritz S., Füssel S., Wirth M.
Institutes: Universitätsklinikum Carl Gustav Carus, Dept. of Urology, Dresden Johannstadt Nord, Germany

529

SMYD3 drives IGF-1R-AKT pathway activation in bladder cancer
Institutes: Shandong University, School of Nursing, Jinan, China, 2Shandong University Qilu Hospital, Dept. of Urology, Jinan, China

530

Her2 alterations in muscle-invasive bladder cancer: There is more than protein expression in patient selection for targeted therapy
Institutes: 1Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, 2University of Bern, Dept. of Urology, Bern, Switzerland, 3University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 4University Hospital of Southampton, Dept. of Urology, Hampshire, United Kingdom, 5University of Bern, Institute of Pathology, Bern, Switzerland, 6Hiroshima University, Dept. of Urology, Hiroshima, Japan, 7GenomeDx, Biosciences, Vancouver, Canada

15:15 - 15:25

Molecular subtypes urothelial cancer
M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)